Compare PGY & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGY | DNTH |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | 493 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 5.9B |
| IPO Year | 2021 | 2018 |
| Metric | PGY | DNTH |
|---|---|---|
| Price | $18.47 | $92.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $34.50 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 1.9M | 593.4K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 116.43 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $1,301,360,000.00 | $2,036,000.00 |
| Revenue This Year | $14.27 | N/A |
| Revenue Next Year | $14.39 | $29.48 |
| P/E Ratio | $26.97 | ★ N/A |
| Revenue Growth | ★ 26.07 | N/A |
| 52 Week Low | $10.40 | $32.28 |
| 52 Week High | $35.55 | $117.88 |
| Indicator | PGY | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 47.05 | N/A |
| Support Level | $20.34 | N/A |
| Resistance Level | $23.45 | N/A |
| Average True Range (ATR) | 0.99 | 0.00 |
| MACD | -0.21 | 0.00 |
| Stochastic Oscillator | 21.30 | 0.00 |
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.